Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAFV600E mutation

Susana García-Silva, Alberto Benito-Martín, Sara Sánchez-Redondo, Alberto Hernández-Barranco, Pilar Ximénez-Embún, Laura Nogués, Marina S. Mazariegos, Kay Brinkmann, Ana Amor López, Lisa Meyer, Carlos Rodríguez, Carmen García-Martín, Jasminka Boskovic, Rocío Letón, Cristina Montero, Mercedes Robledo, Laura Santambrogio, Mary Sue Brady, Anna Szumera-Ciećkiewicz, Iwona KalinowskaJohan Skog, Mikkel Noerholm, Javier Muñoz, Pablo L. Ortiz-Romero, Yolanda Ruano, José L. Rodríguez-Peralto, Piotr Rutkowski, Héctor Peinado

Research output: Contribution to journalArticlepeer-review

88 Scopus citations

Abstract

Liquid biopsies from cancer patients have the potential to improve diagnosis and prognosis. The assessment of surrogate markers of tumor progression in circulating extracellular vesicles could be a powerful non-invasive approach in this setting. We have characterized extracellular vesicles purified from the lymphatic drainage also known as exudative seroma (ES) of stage III melanoma patients obtained after lymphadenectomy. Proteomic analysis showed that seroma-derived exosomes are enriched in proteins resembling melanoma progression. In addition, we found that the BRAFV600E mutation can be detected in ES-derived extracellular vesicles and its detection correlated with patients at risk of relapse.

Original languageEnglish (US)
Pages (from-to)1061-1070
Number of pages10
JournalJournal of Experimental Medicine
Volume216
Issue number5
DOIs
StatePublished - May 1 2019

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAFV600E mutation'. Together they form a unique fingerprint.

Cite this